3‑Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer

Yang,San‑Duk; Ahn,So  Hee; Kim,Jong‑Il

doi:10.3892/ol.2017.7560

3‑Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer

Authors:
- San‑Duk Yang
- So Hee Ahn
- Jong‑Il Kim
View Affiliations

Affiliations: Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 110‑799, Republic of Korea, Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul 110‑799, Republic of Korea
Published online on: December 8, 2017 https://doi.org/10.3892/ol.2017.7560
Pages: 2611-2618

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) is the second leading cause of mortality from gynecological malignancies and has the highest mortality rate worldwide. As it is commonly asymptomatic during the early stages of the disease, >70% of patients with OC are diagnosed at advanced stages with metastasis. Despite treatment methods, including optimal debulking surgery and chemotherapy with the platinum‑based drug cisplatin, OC recurrence is often inevitable, with an overall 5‑year survival rate of 45%, mostly due to the steady development of cisplatin resistance. To identify genes involved in cisplatin resistance, the present study determined the half‑maximal inhibitory concentrations of eight different OC cell lines and classified them into two groups (sensitive and resistant). mRNA expression was analyzed with GeneChip Human Gene 1.0 ST Arrays, and DNA methylation profiles were evaluated with the HumanMethylation450 BeadChip. Using an integrated approach of analyzing gene expression levels and DNA methylation profiles simultaneously, 26 genes were selected that were differentially expressed and methylated between the resistant and sensitive groups. Among these 26 genes, 3‑oxoacid CoA transferase 1 (OXCT1), which was demonstrated to be downregulated and hypermethylated at promoter CpGs in the cisplatin‑resistant group compared with the cisplatin‑sensitive group, was selected for further investigation. Treatment with a DNA methyltransferase inhibitor restored hypermethylation‑mediated gene silencing of OXCT1 in the cisplatin‑resistant group, but not in the cisplatin‑sensitive group. Furthermore, overexpression of OXCT1 conferred sensitivity to cisplatin in OC cells. The results of the present study suggest that OXCT1 serves an important role in conferring cisplatin sensitivity, and may provide a potential therapeutic target for cisplatin chemotherapy in patients with recurrent OC.

View Figures

View References

1	Lowe KA, Chia VM, Taylor A, O'Malley C, Kelsh M, Mohamed M, Mowat FS and Goff B: An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 130:107–114. 2013. View Article : Google Scholar : PubMed/NCBI
2	Notani PN: Global variation in cancer incidence and mortality. Curr Sci-Bangalore. 81:465–474. 2001.
3	Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE and Goff BA: Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of gynecologic oncologists recommendations. Am J Obstet Gynecol. 204:466–478. 2011. View Article : Google Scholar : PubMed/NCBI
4	Ruan Z, Liu J and Kuang Y: Isolation and characterization of side population cells from the human ovarian cancer cell line SK-OV-3. Exp Ther Med. 10:2071–2078. 2015. View Article : Google Scholar : PubMed/NCBI
5	Borley J, Wilhelm-Benartzi C, Brown R and Ghaem-Maghami S: Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer. 107:1069–1074. 2012. View Article : Google Scholar : PubMed/NCBI
6	Mantia-Smaldone GM, Edwards RP and Vlad AM: Targeted treatment of recurrent platinum-resistant ovarian cancer: Current and emerging therapies. Cancer Manag Res. 3:25–38. 2011.PubMed/NCBI
7	Lopez J, Percharde M, Coley HM, Webb A and Crook T: The context and potential of epigenetics in oncology. Br J Cancer. 100:571–577. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bird A: Does DNA methylation control transposition of selfish elements in the germline? Trends Genet. 13:469–472. 1997. View Article : Google Scholar : PubMed/NCBI
9	Thiel G, Lietz M and Hohl M: How mammalian transcriptional repressors work. Eur J Biochem. 271:2855–2862. 2004. View Article : Google Scholar : PubMed/NCBI
10	Suzuki MM and Bird A: DNA methylation landscapes: Provocative insights from epigenomics. Nat Rev Genet. 9:465–476. 2008. View Article : Google Scholar : PubMed/NCBI
11	Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, Califano JA and Sidransky D: Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res. 70:2870–2879. 2010. View Article : Google Scholar : PubMed/NCBI
12	Chen CC, Lee KD, Pai MY, Chu PY, Hsu CC, Chiu CC, Chen LT, Chang JY, Hsiao SH and Leu YW: Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells. Cancer Cell Int. 15:982015. View Article : Google Scholar : PubMed/NCBI
13	Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, Lin SP, Lin WC, Lee HY and Yu MH: Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer. 127:555–567. 2010. View Article : Google Scholar : PubMed/NCBI
14	Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI
15	Nam GH, Ahn K, Bae JH, Cho BW, Park KD, Lee HK, Yang YM, Kim TH, Seong HH, Han K and Kim HS: Identification of ORF sequences and exercise-induced expression change in thoroughbred horse OXCT1 gene. Gene. 496:45–48. 2012. View Article : Google Scholar : PubMed/NCBI
16	Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:Article32004. View Article : Google Scholar : PubMed/NCBI
17	Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B. 57:289–300. 1995.
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Zhang YW, Zheng Y, Wang JZ, Lu XX, Wang Z, Chen LB, Guan XX and Tong JD: Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics. 9:896–909. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wang G, Reed E and Li QQ: Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep. 12:955–965. 2004.PubMed/NCBI
21	Shen DW, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
22	Sanchez-Alvarez R, Martinez-Outschoorn UE, Lin Z, Lamb R, Hulit J, Howell A, Sotgia F, Rubin E and Lisanti MP: Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism: Implications for breast cancer prevention. Cell Cycle. 12:289–301. 2013. View Article : Google Scholar : PubMed/NCBI
23	Shi S, Wang Q, Xu J, Jang JH, Padilla MT, Nyunoya T, Xing C, Zhang L and Lin Y: Synergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagy-mediated apoptosis. Oncotarget. 6:1640–1651. 2015. View Article : Google Scholar : PubMed/NCBI
24	Kimmelman AC: The dynamic nature of autophagy in cancer. Genes Dev. 25:1999–2010. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FK, Yu J and Sung JJ: The autophagic paradox in cancer therapy. Oncogene. 31:939–953. 2012. View Article : Google Scholar : PubMed/NCBI